Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

Heber Siachoque, Milcíades Ibañez

Resultado de la investigación: Contribución a RevistaArtículo

Resumen

Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p
Idioma originalEnglish (US)
Páginas (desde-hasta)375-381
Número de páginas7
PublicaciónColombia Medica
EstadoPublished - oct 1 2007

Huella dactilar

Hepatitis B Vaccines
Synthetic Vaccines
Colombia
Genes
Anti-Idiotypic Antibodies
Vaccination
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Health

Citar esto

@article{058c02e41c1044a6b31751002d399fee,
title = "Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia",
abstract = "Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7{\%} (≥10 U/1), decreasing significantly with the worker's age (p",
author = "Heber Siachoque and Milc{\'i}ades Iba{\~n}ez",
year = "2007",
month = "10",
day = "1",
language = "English (US)",
pages = "375--381",
journal = "Colombia Medica",
issn = "0120-8322",
publisher = "Universidad del Valle",

}

Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia. / Siachoque, Heber; Ibañez, Milcíades.

En: Colombia Medica, 01.10.2007, p. 375-381.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia

AU - Siachoque, Heber

AU - Ibañez, Milcíades

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

AB - Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p

M3 - Article

SP - 375

EP - 381

JO - Colombia Medica

JF - Colombia Medica

SN - 0120-8322

ER -